Capadenoson in Angina Pectoris
Phase 2
Withdrawn
- Conditions
- Chronic Stable Angina
- Interventions
- Drug: Placebo
- Registration Number
- NCT00518921
- Lead Sponsor
- Bayer
- Brief Summary
This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- The primary diagnosis is chronic stable angina of mild-moderate intensity as defined by the Canadian Cardiovascular Society Functional Class II-III, in the presence of definitive coronary artery disease.
- Male or female subjects aged 35 to 75 years (if female, only if postmenopausal or permanently sterilized)
- Stable angina of mild-moderate intensity (Canadian class II-III) with anti-anginal medication not changed for the last 5 weeks
Exclusion Criteria
- Inability to withdraw current anti-anginal therapy
- Inability to withdraw any concomitant therapy that would interfere with interpretation of study results
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 3 Capadenoson (BAY 68-4986) - Arm 1 Capadenoson (BAY 68-4986) - Arm 2 Capadenoson (BAY 68-4986) - Arm 4 Placebo -
- Primary Outcome Measures
Name Time Method Total exercise time 28 days for ETT and 42 days for safety
- Secondary Outcome Measures
Name Time Method Time to angina onset 28 days